Evidence map›Paper›PMID 37425794›Full record

ArticlebioRxiv : the preprint server for biology2023

Reprogramming human B cells with custom heavy chain antibodies.

Geoffrey L Rogers, Chun Huang, Atishay Mathur, Xiaoli Huang, Hsu-Yu Chen, Kalya Stanten, Heidy Morales, Chan-Hua Chang, Eric J Kezirian, Paula M Cannon

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Geoffrey L RogersDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Chun HuangDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Atishay MathurDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Xiaoli HuangDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Hsu-Yu ChenDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Kalya StantenDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Heidy MoralesDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Chan-Hua ChangDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Eric J KezirianDepartment of Otolaryngology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Paula M CannonDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
I4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0M
Primate CoreU19HL156247 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCADDEN, DAVID T · 2020 to 2024
$14.6M
JMJD3 Regulates Abdominal Aortic Aneurysm ExpansionR01HL156274 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GALLAGHER, KATHERINE ANN · 2021 to 2022
$1.1M
Gene edited B cells to co-express CNS-targeted antibodiesR21MH130178 · NIMH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CANNON, PAULA M · 2022 to 2023
$454k
NCI NIH HHS P30 CA014089NHLBI NIH HHS R01 HL156274NHLBI NIH HHS U19 HL156247NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164561NIMH NIH HHS R21 MH130178
6 · The paper itself

Abstract

We describe a genome editing strategy to reprogram the immunoglobulin heavy chain (IgH) locus of human B cells to express custom molecules that respond to immunization. These heavy chain antibodies (HCAbs) comprise a custom antigen-recognition domain linked to an Fc domain derived from the IgH locus and can be differentially spliced to express either B cell receptor (BCR) or secreted antibody isoforms. The HCAb editing platform is highly flexible, supporting antigen-binding domains based on both antibody and non-antibody components, and also allowing alterations in the Fc domain. Using HIV Env protein as a model antigen, we show that B cells edited to express anti-Env HCAbs support the regulated expression of both BCRs and antibodies, and respond to Env antigen in a tonsil organoid model of immunization. In this way, human B cells can be reprogrammed to produce customized therapeutic molecules with the potential for

Identifiers

PMID37425794
PMCPMC10327003
OpenAlexW4382654401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.